WAGUE Daouda¹*, CISSE Mouhamet², Carlos Nouatin², Diop Sagar³, Sy ELHADJI Cheikh Ndiaye⁴, Barry LOUCENY Fatoumata², CISSE Yakhiya⁵, MBAYE Maguette⁶ and THIOUB Mbaye⁶

¹Neurosurgeon, CHM Touba, Diourbel, Senegal
²Neurosurgery resident, Centre Hospitalier National Universitaire de Fann, Senegal
³Neurosurgeon, Hopital Principal de Dakar, Senegal
⁴Neurosurgeon, Cheikh Anta Diop University, Senegal
⁵Neurosuregeon, CHRThies, Senegal
⁶Professor of Neurosurgery, Cheikh Anta Diop University, Senegal

*Corresponding Author: WAGUE Daouda, Neurosurgeon, CHM Touba, Diourbel, Senegal.

Received: May 15,2022; Published: June 24, 2022

Abstract

Background: Brain tumor surgery requires special equipment but also remains expensive around the world. The aim of this study is to share our experience in brain tumor surgery and the difficulties we encountered (socioeconomic restraints and lack of equipment) to perform brain tumor surgery in low-income country.

Methodology: we did retrospective study in one year, we included all patient who undergone craniotomy for tumor resection at Matlaboulfawzaini hospital. We compared costs of care from our hospital to costs of referral hospital in our capital City.

Results: The study is based on 11 patients.06 males and 05 females (sex-ratio:1,2). The average age was 47 years old. The average cost from diagnostic to discharge was $715 in our hospital and ranging from $400 to $1200 whereas in capital City referral Hospital, it was $1450 ranging from $850 to $2000.The most common tumor types were meningiomas and gliomas found in 36% each fellow by metastatic disease in 27%. Surgery was performed in all case. After 01 month of follow up the 04 patients diagnosed with meningioma had completely recovered. Between 03-06 months of follow up we noted tumor recurrence in 03/4 (75%) patients who had been diagnosed with a glial tumor

and 04 (36%) patients died in this study.

Conclusion: the management of brain tumor is still difficult in our region. It’s remain expensive for people despite efforts to reduce cost but also the lack of equipment. However, despite all these difficulties, the results are satisfactory.

Keywords: Tumor; Surgery; Socioeconomic; Equipment; Brain

References

1. JDN: Salaire moyen au senegal. Banque mondial (2019).
2. Ahmed E Helal., et al. “Socioeconomic restraints and brain tumor surgery in low-income countries”. Neurosurgical Focus 4 (2018): E11.
3. Latif AZ., et al. “The costs of managing patients with malignant glioma at a neuro-oncology clinic”. British Journal of Neurosurgery 12 (1998): 118-122.
4. Long DM., et al. “Outcome and cost of craniotomy performed to treat tumors in regional academic referral centers”. Neurosurgery 52 (2003): 1056-1065.
5. Martino J., et al. “Cost-utility of maximal safe resection of WHO grade II gliomas within eloquent areas”. Acta Neurochirurgica (Wien) 155 (2013): 41-50.
6. Yarascavitch BA., et al. “Levels of evidence in the neurosurgical literature: more tribulations than trials”. Neurosurgery 71 (2012): 1131-1138.
7. Zacharia BE., et al. “Incidence, cost, and mortality associated with hospital-acquired conditions after resection of cranial neoplasms”. Neurosurgery 74 (2014): 638-647.
8. Herring B and Trish E. “Explaining the growth in US health care spending using state-level variation in income, insurance, and provider market dynamics”. Inquiry 52 (2015): 4695801561897.
9. Sneh-Arbib O., et al. “Surgical site infections following craniotomy focusing on possible post-operative acquisition of infection: prospective cohort study”. European Journal of Clinical Microbiology and Infectious Diseases 32 (2013): 1511-1516.
10. Ubong Ekpene., et al. “Pattern of intracranial tumours in a tertiary hospital in Ghana”. Ghana Medical Journal 2 (2018): 79-83.
11. Ibebuike K., et al. “Meningiomas among intracranial neoplasms in Johannesburg, South Africa: prevalence, clinical observations and review of the literature”. African Health Sciences1 (2013): 118-121.
12. Robin A Buerki., et al. “An overview of meningiomas”. Future Oncology 21 (2018): 2161-2177.
13. Leland Rogers., et al. “Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review”. Journal of Neurosurgery 1 (2015): 4-23.
14. Walter Taal., et al. “Chemotherapy in glioma”. CNS Oncology 3 (2015): 179-192. 
15. Lakshmi Nayak and David A Reardon. “High-grade Gliomas”. Continuum (Minneap Minn) 6 (2017): 1548-1563.
16. Ricky Chen., et al. “Targeted Therapeutics in Patients with High-Grade Gliomas: Past, Present, and Future”. Current Treatment Options in Oncology 8 (2016): 42.
17. Ostrom QT., et al. “American Brain Tumor Association Adolescent and Young Adult Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012”. NeuroOncology1 (2016): 1-50.
18. Stupp R., et al. “Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial”. Lancet Oncology 5 (2009): 459-466.
19. Altaf Ali Laghari., et al. “Role of surgery in brain metastases”. Journal Of Pakistan Medical Association 8 (2017): 1299-1300.
20. MacGee EE. “Surgical treatment of cerebral metastases from lung cancer: the effect on quality and duration of survival”. Journal of Neurosurgery 35 (1971): 416-420.
21. Patchell RA., et al. “A randomized trial of surgery in the treatment of single metastases to the brain”. NEJM 322 (1990): 494-500.

Citation

Citation: WAGUE Daouda., et al. “Surgery Management of Brain Tumor in Low Income City: Rural Experience and Socioeconomic Restraints". Acta Scientific Neurology 5.7 (2022): 40-46.

Copyright

Copyright: © 2022 WAGUE Daouda., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.